DDInter593 DDInter1658
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Doxepin {u} (Compound) resembles {v} (Compound) Thiothixene
Doxepin {u} (Compound) resembles {v} (Compound) Imipramine
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Cyclobenzaprine
Doxepin {u} (Compound) binds {v} (Gene) HTR2A
Doxepin {u} (Compound) upregulates {v} (Gene) MCOLN1
Doxepin {u} (Compound) palliates {v} (Disease) atopic dermatitis
Doxepin {u} (Compound) downregulates {v} (Gene) FAM69A
Doxepin {u} (Compound) causes {v} (Side Effect) Elevated mood
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Doxepin (Compound) resembles Thiothixene (Compound)
Doxepin (Compound) resembles Imipramine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine
Doxepin (Compound) binds HTR2A (Gene)
Doxepin (Compound) upregulates MCOLN1 (Gene)
Doxepin (Compound) palliates atopic dermatitis (Disease)
Doxepin (Compound) downregulates FAM69A (Gene)
Doxepin (Compound) causes Elevated mood (Side Effect)